


Certification under 37 CFR 1.8

I hereby certify that this paper (along with any paper referred to as being associated herewith) is being electronically filed with the US Patent and Trademark Office on October 12, 2010.



Valerie Neymeyer-Tynkov

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:	09/890,335
Applicant:	Cevc, et al.
Examiner:	Brian Gangle
Art Unit:	1645
Title:	Non-invasive vaccination through the skin
Customer No.:	85965

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

This letter and the attached form PTO/SB/08a are submitted after allowance of the present application but before payment of the issue fee. The fee set forth in 37 CFR 1.17(p) is submitted herewith. The Commissioner is authorized to charge Deposit Account No. 50-4939 in the event that any fees are deemed as due in this application, or to credit any overpayment.

Information submitted in this IDS is not meant to indicate that a search has been made, or that any given document is prior art in the context of the present invention.

This IDS is submitted within 3 months of issuance of a communication from the Japanese Patent Office in a Japanese application counterpart to US Patent Application No. 09/890,371, described as a copending application to the present application at page 1 of the present application. The IDS filed in this application on August 5, 2010 included documents cited by the Japanese Patent Office in that communication. The English language summary of JP 8-183742 ("Ref. 3") submitted with the August 2010 IDS indicates that the present invention was published and disclosed by Aramaki, Vaccine 12(13):1241-5(1994), listed on the IDS submitted herewith. Aramaki discloses conventional liposomes (1:1 lipid:cholesterol molar ratio), similar to those described in Examples 22-29 of the present

application. This IDS is to disclose the Aramaki document, presumably cited by the Japanese Patent Office, and inadvertently omitted from the August 5, 2010 IDS.

Information disclosed herein and throughout prosecution of this application is believed to be complete and within the meaning of the duty to disclose information and the duty of good faith and candor imposed by the USPTO. In view of recent Federal Circuit caselaw, Applicant notes that no information that should be submitted in compliance with these duties has been intentionally omitted from this letter or from the accompanying Information Disclosure Statements and documents attached thereto. In the event that any material, non-cumulative information is deemed missing, it is noted that such omission was made without any intent to withhold information from the USPTO.

Respectfully submitted,



Valerie Neymeyer-Tynkov

Reg. No. 46,956

Neymeyer-Tynkov LLC

20 N. Clark St. Suite 600

Chicago, IL 60602

Phone: 312/965-1969